Last reviewed · How we verify
Anti-CD20 antibodies
Anti-CD20 antibodies is a Small molecule drug developed by Hansa Biopharma AB. It is currently FDA-approved. Also known as: Rituximab.
At a glance
| Generic name | Anti-CD20 antibodies |
|---|---|
| Also known as | Rituximab |
| Sponsor | Hansa Biopharma AB |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia (PHASE1, PHASE2)
- Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial (PHASE2)
- Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma (PHASE2)
- A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies (PHASE1)
- Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (PHASE3)
- Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (PHASE1)
- Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-CD20 antibodies CI brief — competitive landscape report
- Anti-CD20 antibodies updates RSS · CI watch RSS
- Hansa Biopharma AB portfolio CI
Frequently asked questions about Anti-CD20 antibodies
What is Anti-CD20 antibodies?
Anti-CD20 antibodies is a Small molecule drug developed by Hansa Biopharma AB.
Who makes Anti-CD20 antibodies?
Anti-CD20 antibodies is developed and marketed by Hansa Biopharma AB (see full Hansa Biopharma AB pipeline at /company/hansa-biopharma-ab).
Is Anti-CD20 antibodies also known as anything else?
Anti-CD20 antibodies is also known as Rituximab.
What development phase is Anti-CD20 antibodies in?
Anti-CD20 antibodies is FDA-approved (marketed).
Related
- Manufacturer: Hansa Biopharma AB — full pipeline
- Also known as: Rituximab
- Compare: Anti-CD20 antibodies vs similar drugs
- Pricing: Anti-CD20 antibodies cost, discount & access